Seer (SEER) Proxy filing summary
Event summary combining transcript, slides, and related documents.
Proxy filing summary
20 Jul, 2026Executive summary
Special Committee of independent directors unanimously rejected an unsolicited acquisition proposal from the Chair and CEO to acquire all outstanding Class A shares for $2.45 per share in cash plus two contingent value rights.
The proposal was deemed to undervalue the company and not reflect its long-term growth prospects, even considering the contingent value rights tied to future technology developments.
The review process was conducted with independent advisors and in accordance with fiduciary duties.
Forward-looking statements highlight risks, uncertainties, and the company's growth potential, with reference to SEC filings for further details.
Voting matters and shareholder proposals
The Special Committee's decision on the acquisition proposal is a key matter for shareholders, emphasizing the board's commitment to maximizing shareholder value.
Board of directors and corporate governance
The Special Committee consisted of independent directors Meeta Gulyani and Nicolas Roelofs, Ph.D., who led the review of the acquisition proposal.
The board acted in line with fiduciary responsibilities and consulted independent advisors during the evaluation process.
Latest events from Seer
- Shareholders are urged to support current directors in a contested board election for continued progress.SEER
Proxy filing22 Jul 2026 - Board urges support for its director nominees to ensure long-term value and strategic growth.SEER
Proxy filing20 Jul 2026 - Board urges support for its nominees to ensure strategic growth and protect shareholder value.SEER
Proxy filing20 Jul 2026 - Board urges support for its nominees to protect long-term value and resist dissident takeover.SEER
Proxy filing14 Jul 2026 - Board recommends voting for its nominees to ensure long-term value and strategic continuity.SEER
Proxy filing14 Jul 2026 - Rapid innovation, global expansion, and strong financials drive leadership in unbiased proteomics.SEER
43rd Annual J.P. Morgan Healthcare Conference 20258 Jul 2026 - 2025 revenue is guided to grow 24% amid strong adoption, innovation, and robust cash reserves.SEER
Q4 20248 Jul 2026 - Q2 revenue fell 23% to $3.1M; guidance cut and $3.7M in shares repurchased amid headwinds.SEER
Q2 20248 Jul 2026 - Vote for the seven incumbent directors to protect long-term value and strategic direction.SEER
Proxy filing8 Jul 2026